Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Suzetrigine (Journavx) is the first non-opioid painkiller to be approved in the US in 20 years. It could help over 80 million ...

The global aspirin drug market is poised for substantial growth over the next decade, with its value expected to increase ...

Nearly one in three Americans over the age of 60 — roughly 19 million people — take aspirin daily, according to a 2021 study.

If you’re in pain and you’re looking for relief in the form of an over-the-counter drug, you’ve got a slew of options.

From smokers to drinkers, those who lived less healthy lifestyles benefited even more from the pain reliever. “Our results show that aspirin can proportionally lower the markedly elevated risk ...

Not ideal for targeted relief: When taking a well-known pain reliever like aspirin or Tylenol, individuals generally know the level of relief they can expect.. This isn’t as clear cut with CBD ...